Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Hi Wednesday. Probably a question best answered by Berm or Burble, but no tumour response (as yet) for 6 does not necessarily mean they wont have one. That's precisely what these trials are for...safety (tick), tolerability (tick), T cell response (tick), then dose ranging and escalation until we find the optimum dosage and frequency. AIMHO.
So tell me if I've got this right...
23 patients have been dosed so far and 100% of them are showing an indicative T cell response (the skin rash). What's more, 14 have so far been scanned and of these, 8 (57%) are either showing no further tumour progression (as is the case with seven)or a reduction of between 30% and 50% (as is the case with one). I presume that without Modi, all of these patients would have expected the disease to progress?
If so, ladies and gentlemen, we are witnessing Scancell literally stopping cancer in its tracks.
Wow!
Hi Berm. Is it not sometimes the case that share options get exercised immediately before a corporate action? If something is in the offing, might that be a reason why Ichor would want to acquire the shares now rather than wait until the end of April?
Hi Ruck. I'm not sure that the scrapping of Zakari and Covidity are necessarily linked. As 'zachari' is the Greek for 'sugar', I suspect it was originally intended for something connected to the GlyMab platform. AIMHO.
Hi Kash. Just because JMC retired from Lilly in 2018, you seem to assume he is 'elderly'. Wrong. He was in his late fifties when he stepped down from Lilly and is currently 63. Hardly decrepit and plenty left in the tank, I'd say...
Jean-Michel brings to Scancell over 25 years of experience in the pharmaceutical and biotechnology industries and a sustained global track record of success in commercial operations as well as in capital raising, US and European public offerings, business development and M&A. Jean-Michel was Vice President for North America Oncology at Eli Lilly, with responsibility for commercialisation of the company's oncology portfolio. Preceding this US-based position, he was Vice President and Managing Director of the Eli Lilly's European Northern Hub, where he was Chair of the Eli Lilly UK Board and a member of Lilly European Executive Committee. Prior to this Jean-Michel served as VP and Chief Marketing Officer at GE Healthcare's Global Headquarters.
Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the board of Kymab until their acquisition by Sanofi. He was also a member of the Immunocore board prior to the company's Nasdaq listing. Jean-Michel currently serves on the boards of Malin PLC, Exact Therapeutics AS, Eracal Therapeutics and Sophia Genetics SA. He has also been Chair of The American Pharmaceutical Group in the UK, as well as a board member of the Association of British Pharmaceutical Industry. Jean-Michel holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands, as well as a PharmD and a PhD in Nuclear Chemistry and Neurobiology from University Paris, France.
Somebody used the word 'Orchestration' the other day and I am beginning to agree. The SCLP share price is in a holding pattern and has been for some while. Meanwhile, corporate actions are happening (Zakari wind-up, interims early etc).
Then we have the RG interview, conducted on Dec 13th, but held back from release until Jan 17th??? Then the full video released (almost like there was an embargo on it) a few minutes after midnight on the 19th.
I do feel that some orchestration is in play. planned 'corporate' actions, ducks in a row, stars becoming aligned.
I really feel w/c 23rd January 2023 might be a momentous one...AIMHO
Have a good weekend all! C.
When asked about commercialisation, at exactly 10 minutes in on the interview, RG mentions GenMab and argenx in the same breath then very quickly moves on. No other companies mentioned - just these two. I wonder whether this nmay have been a slip of the tongue and argenx could be the hitherto unnamed company we entered into a collaboration agreement with in September 2019?
From the RNS at the time:
"Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed its first collaboration and non-exclusive research agreement with a leading antibody technology company to assess its pipeline of monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) that have been enhanced with its new proprietary AvidiMab™ technology."
And from Argenx website:
"At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies"
We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients"
And "Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them"
The agreement was signed before 25th October 2022 so within period. The upfront payment was expected within a few days of the AGM (I think Lundy referred to it in the recording) so w/c 21st November and therefore post-period.